CTTNBP2

Across TCGA pan-cancer cohorts, CTTNBP2 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated CTTNBP2 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CTTNBP2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CTTNBP2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, SKCM, and KICH are the cancer types where CTTNBP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.325	0.719	<.001	40	view →
SKCM	DFS	Median	All	0.369	0.771	<.001	14	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
SCLC	OS	Median	IV	0.137	0.548	.004	12	view →
BLCA	OS	Median	III,IV	0.063	0.582	<.001	12	view →
UCEC	DFS	Median	All	0.917	0.608	.014	10	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
COAD	OS	Median	III,IV	0.186	0.799	<.001	6	view →
DLBC	OS	Median	II,III,IV	0.118	0.802	.025	3	view →
READ	OS	Median	II,III,IV	0.187	0.653	.030	3	view →
LGG	OS	Median	All	0.306	0.799	.009	3	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

CTTNBP2–LUAD (OS)

Open the LUAD breakdown →